Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasm Metastasis 3Carcinoma, Non-Small-Cell Lung 3Nasopharyngeal Carcinoma 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Recurrence 1Melanoma 1Lymphoma 1Lung Neoplasms 1Hodgkin Disease 1Breast Neoplasms 1Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer 1Advanced Malignant Tumors 1

Interventions

Cyclophosphamide 12Etoposide 10Doxorubicin 9Brentuximab Vedotin 8fludarabine phosphate 7Vinblastine 7Dacarbazine 7Bleomycin 7Vincristine 6Melphalan 6camrelizumab 5Radiotherapy 5Nivolumab 5Mycophenolic Acid 5Decitabine 5pembrolizumab 4Rituximab 4Peripheral Blood Stem Cell Transplantation 4Gemcitabine 4Filgrastim 4Cytarabine 4Cyclosporine 4Busulfan 4Bendamustine Hydrochloride 4ABVD protocol 4Tacrolimus 3Prednisone 3N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Ifosfamide 3Carboplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Hodgkin Disease × SHR-1701 × Clear all
NCT05896046 2023-06-15

SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma

Chinese PLA General Hospital

Phase 1/2 Unknown
100 enrolled
Lymphoid

Hodgkin Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡